Ardelyx’s (ARDX) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Ardelyx (NASDAQ:ARDX) in a report published on Friday,Benzinga reports. They currently have a $17.00 price objective on the biopharmaceutical company’s stock.

Several other analysts also recently commented on ARDX. Raymond James Financial restated a “strong-buy” rating and set a $19.00 price objective on shares of Ardelyx in a research report on Thursday, January 8th. Jefferies Financial Group reissued a “buy” rating and set a $15.00 price target on shares of Ardelyx in a report on Tuesday, January 27th. Wedbush boosted their price objective on Ardelyx from $16.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. TD Cowen reaffirmed a “buy” rating on shares of Ardelyx in a research note on Thursday, January 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ardelyx in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $15.09.

Ardelyx Stock Down 15.0%

ARDX stock opened at $5.73 on Friday. The business’s 50-day moving average price is $6.77 and its 200-day moving average price is $6.12. The stock has a market cap of $1.41 billion, a P/E ratio of -22.92 and a beta of 0.57. The company has a quick ratio of 4.11, a current ratio of 4.31 and a debt-to-equity ratio of 1.21. Ardelyx has a twelve month low of $3.21 and a twelve month high of $8.40.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.The firm had revenue of $125.22 million during the quarter, compared to analysts’ expectations of $118.04 million. During the same period in the prior year, the company posted $0.02 earnings per share. The company’s revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts forecast that Ardelyx will post -0.18 EPS for the current year.

Insider Buying and Selling at Ardelyx

In other news, insider Laura A. Williams sold 50,000 shares of Ardelyx stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $6.98, for a total value of $349,000.00. Following the sale, the insider directly owned 361,563 shares of the company’s stock, valued at approximately $2,523,709.74. The trade was a 12.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.80% of the stock is currently owned by insiders.

Institutional Trading of Ardelyx

A number of large investors have recently added to or reduced their stakes in the company. Marshall Wace LLP raised its stake in Ardelyx by 34.2% during the second quarter. Marshall Wace LLP now owns 11,250,652 shares of the biopharmaceutical company’s stock valued at $44,103,000 after purchasing an additional 2,866,843 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Ardelyx in the 2nd quarter worth about $708,000. Stonepine Capital Management LLC bought a new stake in shares of Ardelyx in the 2nd quarter worth about $2,176,000. Y Intercept Hong Kong Ltd raised its position in shares of Ardelyx by 488.0% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 306,547 shares of the biopharmaceutical company’s stock valued at $1,689,000 after buying an additional 254,417 shares in the last quarter. Finally, AIGH Capital Management LLC bought a new position in shares of Ardelyx in the 3rd quarter valued at about $1,094,000. Institutional investors own 58.92% of the company’s stock.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Strong commercial growth — IBSRELA revenue grew 73% in 2025 to $274.2M and total revenues reached $407.3M, demonstrating meaningful top-line momentum that supports future cash flow potential. Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue beat — Q4 revenue of $125.2M topped analyst estimates (~$118M), showing continued commercial execution even as EPS missed. MarketBeat Q4 results summary
• Positive Sentiment: Bullish analyst support — BTIG reaffirmed a buy rating and set a $17 price target, and at least one firm reportedly raised its target sharply (~+80%), showing divergent analyst views and potential upside if sentiment improves. Benzinga note on BTIG rating
• Neutral Sentiment: Earnings call and disclosures — the full Q4 earnings call transcript is available; management reiterated the XPHOZAH access strategy and said the company is well-capitalized to pursue growth and development programs. Investors will parse the call for guidance on margins and R&D spend. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Data noise on short interest — several data feeds reported large short-interest “increases” but with zero shares and NaN changes, indicating erroneous/unclear short-interest reporting rather than a meaningful squeeze or piling on. Investors should treat those items cautiously.
• Negative Sentiment: EPS miss and margin concerns — Ardelyx reported EPS of ($0.01) vs. consensus $0.02, and commentary showed heavy operational spend that clouds near-term profitability; that miss is the primary near-term driver of selling pressure. Zacks Q4 EPS coverage
• Negative Sentiment: Mixed investor reaction to outlook — post-earnings commentary and coverage highlighted concerns about the IBSRELA outlook and high operating expenses, which prompted the stock decline despite strong sales numbers. Seeking Alpha: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.